HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J9060 | Cisplatin | Platinol, Platinol-AQ | 10 mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 1978 | Jan 1, 1984 | In Use | ||
S0108 | Mercaptopurine | Mercaptopurine | 50 mg | Chemotherapy | Antimetabolite | Purine Analog | Yes | 1953 | Apr 1, 2002 | In Use | ||
J9324 | Pemetrexed disodium | Pemrydi-rtu | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2023 | Dec 7, 2023 | In Use | ||
NA | Vorinostat | Erivedge | 100 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2006 | In Use | |||
NA | Quizartinib | Vanflyta | Multiple | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Yes | 2023 | In Use | |||
NA | ixazomib | Ninlaro | 2.3 mg | Chemotherapy | Proteasome Inhibitor | 20S | Yes | 2015 | In Use | |||
J9248 | Melphalan (Hepzato) | Hepzato | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2023 | Apr 17, 2024 | In Use | ||
NA | Rucaparib | Rubraca | 200 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
J9247 | Melphalan flufenamide | Pepaxto | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2021 | Sep 27, 2021 | Mar 26, 2025 | No Longer Used | |
NA | ixazomib | Ninlaro | 3 mg | Chemotherapy | Proteasome Inhibitor | 20S | Yes | 2015 | In Use | |||
J9249 | Melphalan (Apotex) | Melphalan (Apotex) | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2017 | Apr 17, 2024 | In Use | ||
NA | Bromocriptine Mesylate | Parlodel | Chemotherapy | Dopamine Agonist | Ergot Derivative | Yes | 1978 | In Use | ||||
NA | Dasatinib | Sprycel | 140 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
NA | Niraparib | Zejula | 100 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
S0176 | Hydroxyurea | Hydrea | 500 mg | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Yes | 1967 | Jan 1, 2002 | In Use | ||
NA | Vemurafenib | Zelboraf | 240 mg | Chemotherapy | Enzyme Inhibitor | BRAF | Yes | 2011 | In Use | |||
NA | Panobinostat | Farydak | 20 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
NA | Selinexor | Xpovio | 20mg, 40mg, 50mg, 60mg | Chemotherapy | Enzyme Inhibitor | XPO1 | Yes | 2019 | In Use | |||
NA | olaparib | Lynparza | 50 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2014 | In Use | |||
J9600 | Porfimer | Photofrin | 75 mg | Chemotherapy | Photosensitizing Agent | Cytotoxin | No | 1995 | Jan 1, 1998 | In Use | ||
NA | venetoclax | Venclexta | 50 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
J9096 | Cyclophosphamide | Cyclophosphamide lyophilized | 1 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | Dec 31, 2010 | No Longer Used | |
Lazertinib | Lazcluze | 80mg, 240mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2024 | In Use | ||||
NA | Tepotinib Hydrochloride | Tepmetko | 225mg | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Yes | 2021 | In Use | |||
J9342 | Thiotepa (not otherwise specified) | Thiotepa | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | No | 2001 | Jul 9, 2025 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.